Lupin, Endoceutics focus on women's health in Canada
Lupin, Endoceutics focus on women's health in Canada
09 March 2021 | News
Source credit: Shutterstock
Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, has announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialise Intrarosa® in Canada.
Intrarosa® is Endoceutic’s flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.
Commenting on the partnership, Dr Sofia Mumtaz, President, Lupin Pharma Canada said, “We are very pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. Intrarosa will not only expand and strengthen our product portfolio into women’s health in Canada but will cater to satisfy the unmet medical needs.”